Hodgkin Lymphoma — Expanded Access Programs
Overview
Right2Hope maintains a directory of 36 expanded access programs, clinical trials, and compassionate use pathways listed for Hodgkin Lymphoma. Each entry below was sourced from sponsor disclosures and public clinical-trial registries. Use this hub to understand the breadth of ongoing research, identify sponsors with hodgkin lymphoma programs, and link out to specific protocols for eligibility, contact, and request details. Of these, 11 programs are currently active or recruiting, with the remaining 25 in other lifecycle stages. Sponsors actively running programs in this area include M.D. Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, St. Jude Children's Research Hospital, Masonic Cancer Center, University of Minnesota, Merck Sharp & Dohme LLC, and others.
By recruiting status
Snapshot of where every Hodgkin Lymphoma program currently sits in its lifecycle.
- Active / Recruiting11
- Inactive25
Top sponsors
Organisations running the most Hodgkin Lymphoma programs in the directory.
- M.D. Anderson Cancer Center5 programs
- Memorial Sloan Kettering Cancer Center5 programs
- St. Jude Children's Research Hospital4 programs
- Masonic Cancer Center, University of Minnesota2 programs
- Merck Sharp & Dohme LLC2 programs
- New York Medical College2 programs
- Thomas Jefferson University2 programs
- AstraZeneca1 program
- AVM Biotechnology Inc1 program
- Dana-Farber Cancer Institute1 program
Hodgkin Lymphoma programs (36)
Sorted by recruiting status, then alphabetically by program name. Click any program to view eligibility, locations, and sponsor contact details.
- Study on Carmustine With and Without Ethanol for Lymphoma Patients — VIVUS LLC
- Study on Using A(B)VD Followed by Nivolumab for Initial Treatment in Higher Risk Hodgkin Lymphoma Patients — Memorial Sloan Kettering Cancer Center
- Study on BrECADD Therapy for Stage 2 B-IV Hodgkin Lymphoma — University of Miami
- Study on Chemotherapy With or Without Radiation for Young Patients With Favorable-Risk Hodgkin Lymphoma — St. Jude Children's Research Hospital
- Cord Blood Transplantation for Children and Young Adults with Blood Cancer — Memorial Sloan Kettering Cancer Center
- Study on Ipilimumab With or Without Nivolumab for Relapsed or Hard-to-Treat Classic Hodgkin's Lymphoma — Dana-Farber Cancer Institute
- Study on Using Mozobil for Stem Cell Transplantation — Thomas Jefferson University
- Study on the Safety and Effectiveness of Pembrolizumab with Chemotherapy in Children and Young Adults with Classical Hodgkin Lymphoma — Merck Sharp & Dohme LLC
- Study on Modified Donor Blood Cell Transplantation for Children and Young Adults with High-Risk Blood Cancers — St. Jude Children's Research Hospital
- Home-Based Cancer Treatment Program for Patients in the Florida Panhandle and Nearby Areas — Mayo Clinic
- Study on MGTA-456 for Patients with High-Risk Cancer — Masonic Cancer Center, University of Minnesota
- Study on Frontline Therapy for Advanced Classical Hodgkin Lymphoma — Takeda
- Phase II Study of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide for Patients with Relapsed B-cell Non-Hodgkin Lymphoma — M.D. Anderson Cancer Center
- Study on BV-AVD Treatment for People with Bulky Hodgkin Lymphoma — Memorial Sloan Kettering Cancer Center
- Study Comparing Favezelimab/Pembrolizumab with Chemotherapy for Hodgkin Lymphoma That Has Returned or Stopped Responding to Treatment — Merck Sharp & Dohme LLC
- Study on Stem Cell Transplantation for Blood Disorders Using Special Cell Depletion — Mitchell Cairo
- Study on ATLCAR.CD30.CCR4 Cells for Treating CD30+ Hodgkin's Lymphoma — UNC Lineberger Comprehensive Cancer Center
- Study on Using a Patient's Own Stem Cells for Treating Lymphoma — Masonic Cancer Center, University of Minnesota
- Study on Stem Cell Transplant Followed by Polatuzumab Vedotin for B-cell Non-Hodgkin and Hodgkin Lymphoma — New York Medical College
- AZD3470 as Monotherapy and in Combination With Anticancer Agents in Participants With Relapsed/Refractory Haematologic Malignancies. — AstraZeneca
- Study on Brentuximab Vedotin for Early Stage Hodgkin Lymphoma — University College, London
- Study on Chemoradiotherapy with Targeted Immunotherapy for Pediatric Lymphoma — New York Medical College
- Study on Cytokine-Treated Veto Cells for Patients with Blood Cancers After Stem Cell Transplant — M.D. Anderson Cancer Center
- Donor Stem Cell Transplant with Treosulfan, Fludarabine, and Total-Body Irradiation for Treating Blood Cancers — Fred Hutchinson Cancer Center
- Study on Nivolumab and Axatilimab Combination for Patients with Difficult or Returning Classical Hodgkin Lymphoma — University of Utah
- Access to AVM0703 for Patients with Solid Tumors and Blood Cancers — AVM Biotechnology Inc
- Study on Methionine PET/CT Imaging for Cancer Patients — St. Jude Children's Research Hospital
- Study on Nivolumab and Ruxolitinib for Treating Relapsed or Hard-to-Treat Classical Hodgkin Lymphoma — Veronika Bachanova
- Pediatric Classical Hodgkin Lymphoma Study: cHOD17 — St. Jude Children's Research Hospital
- Study on Pembrolizumab and Targeted Radiation Therapy for Early Stage Relapsed or Hard-to-Treat Hodgkin Lymphoma — Memorial Sloan Kettering Cancer Center
- Study on PET Adapted Brentuximab Vedotin and Pembrolizumab with Doxorubicin and Dacarbazine for Classic Hodgkin Lymphoma — M.D. Anderson Cancer Center
- Phase 2 Study of CD70.CAR NK Cells for Treating Difficult or Returning Lymphomas — M.D. Anderson Cancer Center
- Phase I/II Study of CAR.70-Engineered IL15-Modified Cord Blood NK Cells with Chemotherapy for Treating Relapsed or Resistant Blood Cancers — M.D. Anderson Cancer Center
- Phase II Study of Pembrolizumab and GVD for Treating Relapsed or Resistant Hodgkin Lymphoma — Memorial Sloan Kettering Cancer Center
- Study on Reduced-Intensity Conditioning to Lower Treatment-Related Deaths in Patients Undergoing Stem Cell Transplant — Thomas Jefferson University
- Study of the Monoclonal Antibody IMT-009 in Patients with Advanced Solid Tumors or Lymphomas — Immunitas Therapeutics
About this hub
Expanded access programs (sometimes called compassionate use, named-patient programs, or pre-approval access) allow patients with serious or life-threatening conditions such as Hodgkin Lymphoma to receive an investigational therapy outside of a controlled clinical trial when no comparable approved option is available. Eligibility, location, and the application process differ for each program — review the individual program pages below for sponsor contact information, inclusion criteria, and the request workflow. Right2Hope is a 501(c)(3) nonprofit and provides this directory free of charge for patients, caregivers, and treating physicians.
Looking for a different condition? Browse the full Cancer Type hub directory or search the full expanded access program catalog.